A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1
What is the purpose of this trial?
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.
- Trial withMirati Therapeutics, Inc.
- Start Date05/27/2022
- End Date12/01/2022
- Last Updated07/12/2022
- Study HIC#2000026742